Merus NV
MRUS
Company Profile
Business description
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Contact
Uppsalalaan 17
Utrecht3584 CT
NLDT: +31 302538800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
229
Stocks News & Analysis
stocks
Chart of the week: Where do our analysts see value?
This week's chart of the week looks at the under and overvalued sectors in the Australian market.
stocks
Attractive ASX opportunity with high yield
This REIT is undervalued after selloff despite interest-rate and vacancy headwinds.
stocks
Top priorities for new ANZ CEO
ANZ Group needs margin and efficiency improvement rather than market share gains.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,586.90 | 23.50 | -0.27% |
| CAC 40 | 7,421.46 | 1.94 | -0.03% |
| DAX 40 | 20,409.71 | 10.55 | 0.05% |
| Dow JONES (US) | 44,148.56 | 99.27 | -0.22% |
| FTSE 100 | 8,317.21 | 15.59 | 0.19% |
| HKSE | 20,397.05 | 242.00 | 1.20% |
| NASDAQ | 20,034.89 | 347.65 | 1.77% |
| Nikkei 225 | 39,849.14 | 476.91 | 1.21% |
| NZX 50 Index | 12,692.72 | 68.47 | -0.54% |
| S&P 500 | 6,084.19 | 49.28 | 0.82% |
| S&P/ASX 200 | 8,330.30 | 23.30 | -0.28% |
| SSE Composite Index | 3,461.50 | 29.01 | 0.85% |